|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.07.26 - 19:48
|
Ozempic maker Novo Nordisk sues US rival over ′materially misleading′ ads (The Guardian)
|
|
|
Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effectiveOzempic maker Novo Nordisk said on Tuesday it is suing arch US rival Eli Lilly over “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments.The Danish pharmaceuticals heavyweight complained that the US group – which makes rival weight-loss treatments Zepbound and Mounjaro – “intentionally selected outdated studies” that compared Lilly's highest doses against lower doses of Novo Nordisk's medicines. Continue reading......
|
|
|
|
|
|
|
|
|
21.07.26 - 16:48
|
GLP-1 Fight: Novo Sues Eli Lilly Over Nationwide "Deceptive Advertising" Campaign (ZeroHedge)
|
|
|
GLP-1 Fight: Novo Sues Eli Lilly Over Nationwide "Deceptive Advertising" Campaign
Novo Nordisk wrote in a press release that it is suing GLP-1 rival Eli Lilly in federal court in New Jersey, alleging nationwide "deceptive advertising" for Zepbound and Mounjaro. The company claims Lilly misleads consumers by comparing Lilly's highest doses with lower doses of Novo's Wegovy and Ozempic.
Novo claims Lilly's Zepbound advertising campaign relies on outdated studies that exclude the 7.2-milligram dose of Wegovy, approved in March 2026, which produced an average weight loss of about 19%. Novo also stated that there has been no head-to-head trial comparing the highest approved doses of the two drugs.
"A lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which confuses consumers by using outdated studies to compare the highest injectable doses of Lilly's medicines against lower doses of Novo Nordisk's injectable medicines for ob...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
